IO Biotech (IOBT) News Today $1.00 -0.07 (-6.07%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period IO Biotech (NASDAQ:IOBT) Earns "Buy" Rating from HC WainwrightApril 3 at 2:51 AM | americanbankingnews.comPiper Sandler Sticks to Their Buy Rating for IO Biotech (IOBT)April 2 at 3:12 PM | markets.businessinsider.comIO Biotech (NASDAQ:IOBT) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of IO Biotech in a report on Tuesday.April 2 at 8:02 AM | marketbeat.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Increases By 54.8%IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 50,000 shares, a growth of 54.8% from the February 28th total of 32,300 shares. Approximately 0.1% of the company's stock are short sold. Based on an average daily trading volume, of 177,400 shares, the days-to-cover ratio is presently 0.3 days.March 31 at 10:25 AM | marketbeat.comIO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comIO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025March 18, 2025 | finance.yahoo.comIO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025March 18, 2025 | globenewswire.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Increases By 32.9%IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) saw a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 32,300 shares, a growth of 32.9% from the February 13th total of 24,300 shares. Based on an average daily volume of 181,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company's shares are short sold.March 17, 2025 | marketbeat.comIO Biotech (NASDAQ:IOBT) Upgraded at Piper SandlerPiper Sandler raised shares of IO Biotech to a "strong-buy" rating in a report on Wednesday.March 15, 2025 | marketbeat.comPiper Sandler Keeps Their Buy Rating on IO Biotech (IOBT)March 12, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for IO Biotech (NASDAQ:IOBT)HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of IO Biotech in a research note on Wednesday.March 6, 2025 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short InterestIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 24,300 shares, a decrease of 31.0% from the January 31st total of 35,200 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 311,000 shares, the days-to-cover ratio is currently 0.1 days.March 4, 2025 | marketbeat.comIO Biotech Reports 2024 Business HighlightsMarch 4, 2025 | globenewswire.comIO Biotech (IOBT) to Release Quarterly Earnings on TuesdayIO Biotech (NASDAQ:IOBT) will be releasing earnings on Tuesday, March 4.February 25, 2025 | marketbeat.comIO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO ConferenceFebruary 23, 2025 | globenewswire.comIO Biotech to Present at the 45th Annual Cowen Health Care ConferenceFebruary 20, 2025 | globenewswire.comIO Biotech (NASDAQ:IOBT) Shares Up 4.2% - What's Next?IO Biotech (NASDAQ:IOBT) Trading 4.2% Higher - Should You Buy?February 19, 2025 | marketbeat.comIO Biotech announces publication of preclinical data on IO112February 4, 2025 | markets.businessinsider.comIO Biotech advances cancer vaccine candidate IO112February 4, 2025 | msn.comIO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine CandidateFebruary 4, 2025 | globenewswire.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest UpdateIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 45,400 shares, a decline of 68.6% from the December 31st total of 144,400 shares. Approximately 0.1% of the company's stock are sold short. Based on an average daily volume of 358,100 shares, the short-interest ratio is currently 0.1 days.January 28, 2025 | marketbeat.comJefferies maintains IO Biotech Buy rating, $8 target on PFS hopesJanuary 28, 2025 | msn.comIO Biotech completes enrollment in Phase 2 trial of IO102-IO103January 10, 2025 | markets.businessinsider.comIO Biotech Completes Phase 2 Enrollment Ahead Of Schedule For IO102-IO103 Cancer Vaccine TrialJanuary 10, 2025 | markets.businessinsider.comIO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck CancerJanuary 9, 2025 | globenewswire.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 210.5% in DecemberIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 144,400 shares, an increase of 210.5% from the November 30th total of 46,500 shares. Based on an average daily volume of 349,900 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.3% of the shares of the company are sold short.December 26, 2024 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in StockIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) CEO Mai-Britt Zocca bought 12,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.81 per share, for a total transaction of $10,125.00. Following the completion of the acquisition, the chief executive officer now owns 49,891 shares in the company, valued at approximately $40,411.71. This trade represents a 33.43 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.December 23, 2024 | marketbeat.comIO Biotech secures up to €57.5 million in debt financing from the European Investment BankDecember 20, 2024 | globenewswire.comIO Biotech (NASDAQ:IOBT) Shares Down 1.3% - Here's What HappenedIO Biotech (NASDAQ:IOBT) Stock Price Down 1.3% - Should You Sell?December 20, 2024 | marketbeat.comIO Biotech amends bylaws and adjusts fiscal year-endDecember 19, 2024 | uk.investing.comHC Wainwright Cuts Earnings Estimates for IO BiotechIO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of IO Biotech in a research note issued on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earningsNovember 15, 2024 | marketbeat.comPromising Prospects for IO Biotech Driven by Phase 3 Melanoma Study and Strong Financial PositionNovember 14, 2024 | markets.businessinsider.comPositive Outlook for IO Biotech Amid Promising Clinical Developments in Melanoma and Head & Neck Cancer TrialsNovember 13, 2024 | markets.businessinsider.comPromising Clinical Progress and Financial Stability Drive Buy Rating for IO BiotechNovember 13, 2024 | markets.businessinsider.comIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNovember 12, 2024 | globenewswire.comIO Biotech Announces Participation in Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comPromising Potential of IO Biotech: Buy Rating Backed by Strong Phase 2 Data and Strategic Growth PlansNovember 8, 2024 | markets.businessinsider.comIO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNovember 7, 2024 | globenewswire.comIO Biotech Receives Buy Rating Amid Promising Phase 2 Results and Future Potential in Cancer TreatmentsNovember 7, 2024 | markets.businessinsider.comHere's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn SituationNovember 3, 2024 | finance.yahoo.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7%IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 277,100 shares, a drop of 12.7% from the September 30th total of 317,500 shares. Currently, 0.6% of the company's shares are sold short. Based on an average trading volume of 410,000 shares, the days-to-cover ratio is currently 0.7 days.October 29, 2024 | marketbeat.comNovo Holdings A S Has $3.52 Million Position in IO Biotech, Inc. (NASDAQ:IOBT)Novo Holdings A S trimmed its position in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) by 24.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,354,449 shares of the company's stock after seOctober 27, 2024 | marketbeat.comBuy Rating on IO Biotech’s IO102/103 Fueled by Positive KOL Feedback and Phase 2 DataOctober 4, 2024 | markets.businessinsider.comIO Biotech (NASDAQ:IOBT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 4, 2024 | markets.businessinsider.comIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comNovo Holdings A S Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT)Novo Holdings A S lessened its position in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) by 12.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,429,449 shares of the company's stock after selling 658,809 shareSeptember 30, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)September 16, 2024 | markets.businessinsider.comBuy Rating for IO Biotech Backed by Promising ESMO Data and Superior Efficacy of IO102-IO103 Combination TherapySeptember 16, 2024 | markets.businessinsider.comIO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerSeptember 14, 2024 | globenewswire.com Remove Ads Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address IOBT Media Mentions By Week IOBT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOBT News Sentiment▼0.310.57▲Average Medical News Sentiment IOBT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOBT Articles This Week▼51▲IOBT Articles Average Week Remove Ads Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcturus Therapeutics News Today Aquestive Therapeutics News Today Solid Biosciences News Today Monte Rosa Therapeutics News Today Taysha Gene Therapies News Today Esperion Therapeutics News Today Alpha Teknova News Today Atai Life Sciences News Today Atyr PHARMA News Today Candel Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOBT) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IOBT Stock Free IOBT Stock Alerts